Seminars in thrombosis and hemostasis最新文献_第3页

Neutrophil Extracellular Traps: At the Interface of Thrombosis and Comorbidities. 中性粒细胞胞外陷阱：在血栓形成和合并症的界面。

IF 3.6 2区医学

Seminars in thrombosis and hemostasis Pub Date : 2025-03-28 DOI: 10.1055/a-2548-0805

Imre Varjú, Anna Tanka-Salamon, Krasimir Kolev

{"title":"Neutrophil Extracellular Traps: At the Interface of Thrombosis and Comorbidities.","authors":"Imre Varjú, Anna Tanka-Salamon, Krasimir Kolev","doi":"10.1055/a-2548-0805","DOIUrl":"10.1055/a-2548-0805","url":null,"abstract":"Since their discovery in 2004, neutrophil extracellular traps (NETs) have been at the center of multidisciplinary attention. Although a key tool in neutrophil-mediated immunity, these filamentous, enzyme-enriched DNA-histone complexes can be detrimental to tissues and have been identified as an underlying factor in a range of pathological conditions. Building on more than 20 years of research into NETs, this review places thrombosis, the pathological formation of blood clots, in the spotlight. From this point of view, we discuss the structure and formation of NETs, as well as the interaction of their components with the hemostatic system, dissecting the pathways through which NETs exert their marked effect on formation and the dissolution of thrombi. We pay distinct attention to the latest developments in the research of a key player in NET formation, peptidyl-arginine-deiminase (PAD) enzymes: their types, sources, and potential cross-play with the hemostatic machinery. Besides these molecular details, we elaborate on the link between pathological thrombosis, NETs, and widespread conditions that represent a debilitating public health burden worldwide, such as sepsis and neoplasms. Finally, future implications on the treatment of thrombosis-related conditions will be discussed.","PeriodicalId":21673,"journal":{"name":"Seminars in thrombosis and hemostasis","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143531686","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Red Blood Cells in Thrombosis: Active Participants in Clot Formation and Stability: A Systematic Review. 红细胞在血栓形成中的作用：血栓形成和稳定性的积极参与者：一项系统综述。

IF 3.6 2区医学

Seminars in thrombosis and hemostasis Pub Date : 2025-03-28 DOI: 10.1055/a-2552-9525

Amin A Alamin, Amar I O Yahia, Hatim M Hussien

{"title":"Red Blood Cells in Thrombosis: Active Participants in Clot Formation and Stability: A Systematic Review.","authors":"Amin A Alamin, Amar I O Yahia, Hatim M Hussien","doi":"10.1055/a-2552-9525","DOIUrl":"https://doi.org/10.1055/a-2552-9525","url":null,"abstract":"Thrombosis, the formation of blood clots within blood vessels, has traditionally been attributed to platelets and clotting factors. Red blood cells (RBCs) play a significant role in thrombosis by impacting clot formation, stability, and fibrinolysis through mechanisms such as platelet margination, thrombin generation, and microvesicle release. However, their prothrombotic functions remain insufficiently studied. In this systematic review, which follows PRISMA guidelines, the aim is to explore how RBCs contribute to thrombus formation, stabilization, and resolution. This review analyzed peer-reviewed English-language studies and reviews on RBC involvement in thrombosis, focusing on clot formation, stability, and fibrinolysis. Studies in humans and relevant animal models were included, while case reports, non-English studies, and articles lacking methodological details were excluded. The research commenced in September 2024, utilizing PubMed, Scopus, SpringerLink, and Web of Science databases, with searches conducted up to that date. The risk of bias was assessed using the Newcastle-Ottawa Scale, and data were synthesized qualitatively. A total of 37 studies were included. RBCs contribute to thrombosis by influencing blood viscosity, interacting with platelets, and integrating into clots. Procoagulant activity induced by phosphatidylserine exposure and RBC-derived microvesicle products that promote thrombin generation and clot stability were also identified as key mechanisms. In conclusion, RBCs play an active role in thrombosis formation, contributing to clot formation and stability. Targeting RBC-mediated processes, such as aggregation, deformability, and microvesicle release, may offer novel strategies for thrombosis management. Further research and meta-analyses are needed to refine these therapeutic approaches.","PeriodicalId":21673,"journal":{"name":"Seminars in thrombosis and hemostasis","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143743655","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Novel Antidiabetic Drugs and Risk of Venous Thromboembolism: A Literature Review. 新型降糖药与静脉血栓栓塞风险：文献综述。

IF 3.6 2区医学

Seminars in thrombosis and hemostasis Pub Date : 2025-03-28 DOI: 10.1055/a-2546-0353

Qingui Chen, Rayna J S Anijs, Judith P L Verlaan, Luuk J J Scheres, Frederikus A Klok, Suzanne C Cannegieter

{"title":"Novel Antidiabetic Drugs and Risk of Venous Thromboembolism: A Literature Review.","authors":"Qingui Chen, Rayna J S Anijs, Judith P L Verlaan, Luuk J J Scheres, Frederikus A Klok, Suzanne C Cannegieter","doi":"10.1055/a-2546-0353","DOIUrl":"https://doi.org/10.1055/a-2546-0353","url":null,"abstract":"Novel antidiabetic drugs, particularly sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists, have significantly transformed the management landscape for type 2 diabetes mellitus, cardiovascular diseases, and chronic kidney diseases, owing to their well-established cardiorenal protective effects. Given the shared risk factors and comorbidities, it is relevant to consider the potential risk of venous thromboembolism (VTE) in individuals prescribed these novel antidiabetic medications. This literature review aims to summarize currently available evidence on VTE risk associated with novel antidiabetic drugs, including GLP-1 receptor agonists, dipeptidyl-peptidase IV (DPP-4) inhibitors, and SGLT2 inhibitors. Following a comprehensive search on PubMed using relevant keywords and backward reference searching, we identified 25 publications that directly reported on associations between these medications and VTE risk. Findings from these studies, including seven meta-analyses, reveal inconsistent results: some studies suggest that GLP-1 receptor agonists or DPP-4 inhibitors may be associated with increased risk of VTE, whereas SGLT2 inhibitors do not appear to be associated with VTE and may even be a protective factor. A notable limitation of the existing studies is the significant challenge posed by confounding in observational studies, while the randomized controlled trials (RCTs) often concluded with a limited number of VTE events, if it was studied. Furthermore, all identified studies focused on the risk of primary VTE, leaving an important knowledge gap regarding whether these novel antidiabetic drugs may influence the efficacy or safety of anticoagulants used for preventing VTE recurrence. Addressing these gaps presents an important avenue for future research.","PeriodicalId":21673,"journal":{"name":"Seminars in thrombosis and hemostasis","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143743652","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mortality from Pulmonary Embolism in Patients with Post-Coronavirus Disease Syndrome. 冠状病毒后疾病综合征患者肺栓塞死亡率

IF 3.6 2区医学

Seminars in thrombosis and hemostasis Pub Date : 2025-03-28 DOI: 10.1055/a-2552-1829

Giuseppe Lippi, Camilla Mattiuzzi, Emmanuel J Favaloro

引用次数: 0

Anticoagulants in Children with Renal Impairment: A Narrative Review. 儿童肾脏损害的抗凝治疗：一个叙述性的回顾。

IF 3.6 2区医学

Seminars in thrombosis and hemostasis Pub Date : 2025-03-28 DOI: 10.1055/a-2546-0126

Amy L Kiskaddon, Daniel M Witt, Marisol Betensky, Anthony A Sochet, Amanda Memken, Christoph Male, Neil A Goldenberg

{"title":"Anticoagulants in Children with Renal Impairment: A Narrative Review.","authors":"Amy L Kiskaddon, Daniel M Witt, Marisol Betensky, Anthony A Sochet, Amanda Memken, Christoph Male, Neil A Goldenberg","doi":"10.1055/a-2546-0126","DOIUrl":"https://doi.org/10.1055/a-2546-0126","url":null,"abstract":"Venous thromboembolism is a common cause of morbidity and mortality in children with renal disease. To properly treat and prevent thromboembolism in this patient population, it is important to be familiar with the multitude of anticoagulant agents currently available. Many anticoagulant drugs undergo some extent of renal elimination. There are important considerations for the selection, dosing, and monitoring of anticoagulant drugs for patients with renal impairment due to various pharmacokinetic alterations that may occur. While there are data to help guide dosing and monitoring in adults, evidence regarding renal dose adjustment of many anticoagulant drugs in children are limited. For the clinician, anticoagulation management in children with renal impairment presents unique challenges. In addition to considering overall bleeding risk, the extent of renal impairment may vary by patient, making a one-size-fits-all approach to managing these patients difficult. These factors, combined with limited data, can make managing anticoagulation in children with renal impairment a challenge. Therefore, the focus of this review will be to describe the pharmacokinetics of the following anticoagulants in children with impaired renal function: unfractionated heparin, enoxaparin, dalteparin, rivaroxaban, apixaban, edoxaban, fondaparinux, bivalirudin, argatroban, dabigatran, and warfarin.","PeriodicalId":21673,"journal":{"name":"Seminars in thrombosis and hemostasis","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143743558","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Nebulized Heparin in 2025: at the Interface between Promising Benefits and the Need for Further Research. 2025年雾化肝素：在前景看好和需要进一步研究之间的界面。

IF 3.6 2区医学

Seminars in thrombosis and hemostasis Pub Date : 2025-03-28 DOI: 10.1055/a-2552-1886

Giuseppe Lippi, Emmanuel J Favaloro

引用次数: 0

2025 Eberhard F. Mammen Award Announcements: Part I-Most Popular Articles. 2025 Eberhard F. Mammen奖公告：第一部分-最受欢迎的文章。

IF 3.6 2区医学

Seminars in thrombosis and hemostasis Pub Date : 2025-03-25 DOI: 10.1055/s-0045-1806855

Emmanuel J Favaloro

引用次数: 0

Use of Oral Anti-Xa Inhibitor in Prosthetic Mechanical Aortic Valve with Warfarin Hypersensitivity Due to the FIX p.(Ala37Thr) Propeptide Variant: Case Report and Literature Review. 口服抗xa抑制剂在FIX p.（Ala37Thr）前肽变异致华法林过敏的人工机械主动脉瓣中的应用：病例报告及文献复习

IF 3.6 2区医学

Seminars in thrombosis and hemostasis Pub Date : 2025-03-25 DOI: 10.1055/a-2546-7180

Antonella Tufano, Carmine Fierarossa, Ferdinando Cirillo, Ciro Miele, Filomena Capasso, Cristina Mazzaccara, Lucia Micale, Gennaro Vecchione, Marco Castori, Ignazio Frangipane, Luca Mocerino, Ernesto Cimino, Matteo Di Minno

{"title":"Use of Oral Anti-Xa Inhibitor in Prosthetic Mechanical Aortic Valve with Warfarin Hypersensitivity Due to the FIX p.(Ala37Thr) Propeptide Variant: Case Report and Literature Review.","authors":"Antonella Tufano, Carmine Fierarossa, Ferdinando Cirillo, Ciro Miele, Filomena Capasso, Cristina Mazzaccara, Lucia Micale, Gennaro Vecchione, Marco Castori, Ignazio Frangipane, Luca Mocerino, Ernesto Cimino, Matteo Di Minno","doi":"10.1055/a-2546-7180","DOIUrl":"10.1055/a-2546-7180","url":null,"abstract":"Bleeding is the most common side effect during treatment with vitamin K antagonists (VKAs). Sometimes, VKA use causes bleeding episodes due to rare variants in the factor IX (FIX) propeptide that modify the affinity of FIX propeptide to the binding of γ-glutamyl carboxylase. We report on a 51-year-old patient who presented with recurrent spontaneous and severe intramuscular and cutaneous bleedings during VKA (warfarin) treatment for the presence of a prosthetic mechanical aortic valve. Laboratory evaluation revealed INR within the therapeutic range with markedly prolonged aPTT and a large reduction of FIX levels. Laboratory parameters significantly improved when warfarin was switched with low-molecular-weight heparin. Next-generation sequencing analysis revealed the variant p.(Ala37Thr) in the F9 gene, which has been previously associated with VKA sensitivity. As an alternative to warfarin, apixaban 5 mg twice daily and aspirin 100 mg daily were started, with no thrombosis or recurrence of hemorrhage and normalization of INR, aPTT, and FIX levels, at 12-month follow-up. We also performed a literature search across PubMed and Scopus, until January 2025. The analysis evidenced five case reports and two case series. The mechanisms of this rare VKA hypersensitivity have also been reviewed. In conclusion, while VKA hypersensitivity is a rare phenomenon, awareness of this complication and the current accessibility to molecular testing make it important to identify patients at risk. The efficacy/safety of direct thrombin or factor Xa inhibitors in patients with a mechanical heart valve and VKA hypersensitivity due to the F9 p.(Ala37Thr) variant deserves more attention and further investigation.","PeriodicalId":21673,"journal":{"name":"Seminars in thrombosis and hemostasis","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143524324","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Hemostatic Manifestations of Invasive Fungal Infections: A Comprehensive Review of Pathophysiological Mechanisms in Sepsis-Induced Hemostatic Disturbances, with a Focus on the Neonatal Population. 侵袭性真菌感染的止血表现：脓毒症引起的止血障碍的病理生理机制的综合综述，重点是新生儿人群。

IF 3.6 2区医学

Seminars in thrombosis and hemostasis Pub Date : 2025-03-24 DOI: 10.1055/a-2564-7613

Alexandra Lianou, Andreas G Tsantes, Daniele Piovani, Stefanos Bonovas, Irma Lapaj, Eleni Gounari, Argirios E Tsantes, Nicoletta Iacovidou, Rozeta Sokou

{"title":"Hemostatic Manifestations of Invasive Fungal Infections: A Comprehensive Review of Pathophysiological Mechanisms in Sepsis-Induced Hemostatic Disturbances, with a Focus on the Neonatal Population.","authors":"Alexandra Lianou, Andreas G Tsantes, Daniele Piovani, Stefanos Bonovas, Irma Lapaj, Eleni Gounari, Argirios E Tsantes, Nicoletta Iacovidou, Rozeta Sokou","doi":"10.1055/a-2564-7613","DOIUrl":"https://doi.org/10.1055/a-2564-7613","url":null,"abstract":"Sepsis is a life-threatening condition that has challenged many clinicians over the years. The immune and hemostatic systems are the primary pillars of sepsis pathogenesis. Dysregulation of these intricate mechanisms significantly worsens the prognosis. Coagulopathy is a critical aspect of sepsis, with the degree of hemostatic impairment being a key determinant of poor outcomes. Although the concept of sepsis caused by bacteria has been well investigated, the fungal impact in the complexity of sepsis related hemostatic derangement is not yet fully unraveled. In addition, sepsis occurs in patients across all age groups, with a particular concern for neonates, whose immature and vulnerable systems amplify the challenges. Notably, despite the high incidence of fungal septicemia in neonatal intensive care units (NICUs), along with its significant morbidity, mortality, and adverse neonatal outcomes, the impact of fungal sepsis on the neonatal hemostatic system-an essential determinant of prognosis-remains largely unexplored. The present review delves into the pathophysiologic mechanisms of sepsis induced coagulopathy attributed to fungal infection, the mechanisms of fungal involvement in the hemostatic derangement and attempts to contextualize this knowledge within the unique neonatal population. Finally, it aims to raise awareness of the critical need for a deep understanding of this hazardous condition in order to guide the development of optimal therapeutic strategies.","PeriodicalId":21673,"journal":{"name":"Seminars in thrombosis and hemostasis","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143701301","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Unlocking the Potential of MicroRNA Expression: Biomarkers for Platelet Reactivity and Coronary Artery Disease. 解锁MicroRNA表达的潜力：血小板反应性和冠状动脉疾病的生物标志物。

IF 3.6 2区医学

Seminars in thrombosis and hemostasis Pub Date : 2025-03-12 DOI: 10.1055/s-0045-1805041

Peter H Nissen, Oliver Buchhave Pedersen

{"title":"Unlocking the Potential of MicroRNA Expression: Biomarkers for Platelet Reactivity and Coronary Artery Disease.","authors":"Peter H Nissen, Oliver Buchhave Pedersen","doi":"10.1055/s-0045-1805041","DOIUrl":"https://doi.org/10.1055/s-0045-1805041","url":null,"abstract":"Coronary artery disease (CAD) is a leading cause of morbidity and mortality worldwide, with platelet reactivity playing a central role in its pathogenesis. Recent research has identified microRNAs (miRNAs; miRs) as potential biomarkers for CAD, due to their ability to regulate platelet function and reactivity. This review focuses on four key miRNAs-miR-223, miR-126, miR-21, and miR-150-known to influence platelet reactivity and their implications in CAD. miR-223, which is highly expressed in platelets, has shown associations with CAD and myocardial infarction, while miR-126 has been linked to thrombus formation and vascular health. Additionally, miR-21 and miR-150 have also emerged as important players, with roles in platelet reactivity and cardiovascular outcomes. However, despite their potential, the use of miRNAs as clinical biomarkers faces several challenges, including variability in reported results across studies. These inconsistencies often arise from differences in sample material, preanalytical conditions, and normalization strategies. Furthermore, the influence of antiplatelet therapy on miRNA expression adds another layer of complexity, making it difficult to determine whether observed changes in miRNA levels are due to disease states or therapeutic interventions. This review therefore highlights the need for standardization in miRNA research to enhance the reliability of findings. By addressing these methodological challenges, miRNAs could become powerful tools in personalized medicine, aiding in the development of tailored therapeutic strategies for CAD patients and ultimately improving clinical outcomes.","PeriodicalId":21673,"journal":{"name":"Seminars in thrombosis and hemostasis","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143617114","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0